drugset / Trial / NCT02509546
8-Chloroadenosine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase 1/2
Completed
20 enrolled
City of Hope Medical Center
National Cancer Institute (NCI) · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This phase I/II trial studies the side effects and best dose of 8-chloroadenosine and to see how well it works in treating patients with acute myeloid leukemia that has returned after a period of improvement (relapsed) or does not respond to treatment (refractory). Drugs used in chemotherapy, such as 8-chloroadenosine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Timeline
- Start
- 2015-09-02
- Primary completion
- 2021-03-09
- Completion
- 2021-03-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 8-Chloroadenosine | Small molecule | 100 mg/m2 | Intravenous |
| Subject | 8-Chloroadenosine | Small molecule | 200 mg/m2 | Intravenous |
| Subject | 8-Chloroadenosine | Small molecule | 400 mg/m2 | Intravenous |
| Subject | 8-Chloroadenosine | Small molecule | 600 mg/m2 | Intravenous |
| Subject | 8-Chloroadenosine | Small molecule | 800 mg/m2 | Intravenous |